Celldex Therapeutics, Inc. Share Price London S.E.
Stocks
US15117B1035
Biotechnology & Medical Research
| Market Cap | 303.99Cr 263.44Cr 248.99Cr 226.05Cr 423.66Cr 29TCr 426.19Cr 2.97TCr 1.15TCr 15TCr 1.14TCr 1.12TCr 47TCr | P/E 2026 * |
-9.23x | P/E 2027 * | -9.09x |
|---|---|---|---|---|---|
| Enterprise Value | 237.76Cr 206.04Cr 194.74Cr 176.8Cr 331.35Cr 23TCr 333.33Cr 2.32TCr 898.34Cr 12TCr 893.13Cr 873.3Cr 37TCr | EV / Sales 2026 * |
1,171x | EV / Sales 2027 * | 225x |
| Free-Float |
99.73% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Celldex Therapeutics, Inc.
| 1 day | -2.26% |
| Manager | Title | Age | Since |
|---|---|---|---|
Tibor Keler
CTO | Chief Tech/Sci/R&D Officer | 67 | 30/07/2014 |
Anthony Marucci
CEO | Chief Executive Officer | 64 | 01/09/2008 |
Sam Martin
DFI | Director of Finance/CFO | 55 | 01/04/2009 |
| Director | Title | Age | Since |
|---|---|---|---|
Anthony Marucci
BRD | Director/Board Member | 64 | 01/12/2008 |
Harry Penner
CHM | Chairman | 80 | 05/06/2025 |
Herbert Conrad
BRD | Director/Board Member | 93 | 01/03/2008 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.26% | -.--% | - | - | 302.42Cr | |
| +0.22% | +0.07% | -1.90% | +8.24% | 4.58TCr | |
| -4.36% | -5.66% | +338.30% | +516.88% | 4.39TCr | |
| -0.32% | +4.61% | +43.90% | +26.98% | 4.44TCr | |
| +0.46% | -0.83% | +6.38% | +73.76% | 3.94TCr | |
| -0.17% | -3.22% | +10.29% | +38.69% | 3.13TCr | |
| +3.30% | -5.03% | - | - | 1.57TCr | |
| -0.65% | +5.14% | +25.61% | +120.17% | 1.73TCr | |
| +1.66% | +5.30% | +19.25% | +34.93% | 1.47TCr | |
| +0.19% | -1.77% | +80.35% | +31.52% | 1.3TCr | |
| Average | -0.19% | -0.94% | +65.27% | +106.40% | 2.95TCr | |
| Weighted average by Cap. | -0.45% | -0.87% | +76.30% | +125.65% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 20.31L 17.6L 16.64L 15.1L 28.31L 19Cr 28.48L 1.99Cr 76.75L 9.88Cr 76.3L 74.61L 32Cr | 1.07Cr 92.78L 87.69L 79.61L 1.49Cr 102.71Cr 1.5Cr 10Cr 4.05Cr 52Cr 4.02Cr 3.93Cr 166.05Cr |
| Net income | -32Cr -28Cr -26Cr -24Cr -44Cr -3.06TCr -45Cr -312.09Cr -120.6Cr -1.55TCr -119.9Cr -117.24Cr -4.95TCr | -36Cr -31Cr -30Cr -27Cr -50Cr -3.46TCr -51Cr -352.94Cr -136.38Cr -1.76TCr -135.59Cr -132.58Cr -5.6TCr |
| Net Debt | -66Cr -57Cr -54Cr -49Cr -92Cr -6.35TCr -93Cr -647.63Cr -250.25Cr -3.22TCr -248.8Cr -243.28Cr -10TCr | -63Cr -55Cr -52Cr -47Cr -88Cr -6.09TCr -89Cr -620.47Cr -239.76Cr -3.09TCr -238.37Cr -233.07Cr -9.84TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
